Near‑Infrared Photobiomodulation in White‑Matter Disease: From Microglial States to Measurable Endpoints

Jiahao Zhang1, Quanguang Zhang1, J Dedrick Jordan2

  • 1Institute for Cerebrovascular and Neuroregeneration Research (ICNR), Department of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA, 71103, USA.

Insights

Near-infrared photobiomodulation (PBM) shows promise for treating white-matter (WM) injury by modulating microglial states and supporting repair. Further research is needed to optimize dosing and delivery for conditions like traumatic brain injury and dementia.

Area of Science:

  • Neuroscience
  • Biomedical Engineering
  • Regenerative Medicine

Background:

  • White-matter (WM) injury is a key factor in neurological disorders such as multiple sclerosis, traumatic brain injury, Alzheimer's disease, and small-vessel disease.
  • Microglia play a crucial role in the WM injury-to-repair continuum, shifting between inflammatory and repair-competent states.
  • Near-infrared photobiomodulation (PBM) targets mitochondrial redox pathways and inflammatory tone, with varying mechanisms depending on wavelength.

Purpose of the Study:

  • To explore the potential of PBM in mitigating WM injury and promoting repair.
  • To organize WM injury-to-repair logic through microglial state programs.
  • To synthesize mechanism-informed, dose-aware reporting guidance for PBM studies.

Main Methods:

  • Review of existing literature on PBM effects in demyelination and spinal cord injury models.
  • Analysis of PBM mechanisms, particularly wavelength-dependent effects on mitochondrial pathways.
  • Synthesis of guidance for outcome frameworks, including diffusion MRI/DTI and biomarkers (NfL, GFAP, sTREM2).

Main Results:

  • PBM has demonstrated reductions in inflammatory glial markers and improvements in myelin/axon endpoints in animal models.
  • Human evidence suggests PBM is safe, with early trials showing changes in WM metrics and cognitive signals.
  • Dose dependence and depth-limited delivery are critical considerations for PBM efficacy.

Conclusions:

  • PBM offers a potential therapeutic strategy for WM injury by influencing microglial states and supporting repair processes.
  • Standardized reporting and outcome frameworks are essential for advancing PBM research in neurological disorders.
  • Further investigation into indirect/systemic effects may help overcome depth-dose limitations for deeper WM targets.

Related Concept Videos